AMPD3 Polyclonal Antibody
Applications
Reactivity
| Overview | |
| Catalog # | bs-9517R |
| Product Name | AMPD3 Polyclonal Antibody |
| Applications |
ELISA
IHC-P
IHC-F
IF
|
| Reactivity | Human, Mouse, Rat |
| Specifications | |
| Conjugation | Unconjugated |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human AMPD3 |
| Immunogen Range | 21-120/767 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target | |
| Gene ID | 272 |
| Synonyms | Adenosine monophosphate deaminase isoform E; Adenosine monophosphate deaminase 3; AMP aminohydrolase; AMP deaminase 3; AMP deaminase isoform E; Ampd3; AMPD3_HUMAN; Erythrocyte AMP deaminase; Erythrocyte specic AMP deaminase; Erythrocyte type AMP deaminase; Myoadenylate deaminase. |
| Background | AMP deaminase plays a critical role in energy metabolism.Involvement in diseaseDefects in AMPD3 are the cause of adenosine monophosphate deaminase deficiency erythrocyte type (AMPDDE); also known as erythrocyte AMP deaminase deficiency. AMPDDE is a metabolic disorder due to lack of activity of the erythrocyte isoform of AMP deaminase. It is a clinically asymptomatic condition characterized by a 50% increase in steady-state levels of ATP in affected cells. Individuals with complete deficiency of erythrocyte AMP deaminase are healthy and have no hematologic disorders. |
| Application Dilution | |
| ELISA | WB1:300-5000 |
| IHC-P | 1:200-400 |
| IHC-F | IFIHC-P1:50-200 |
| IF | |